Shandong Buchang Pharmaceuticals603858.SHValuation Analysis

As of Oct 19, 2026, Shandong Buchang Pharmaceuticals (603858.SH) trades at a P/E of 65.00x, P/B of 1.53x, P/S of 1.53x, and a dividend yield of 3.92%.
Longitudinal percentile comparison: P/E sits at the 95th percentile over the trailing 10Y window (vs. 73rd percentile over 3Y); P/B sits at the 14th percentile over the trailing 10Y window (vs. 18th percentile over 3Y); P/S sits at the 25th percentile over the trailing 10Y window (vs. 40th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 68th percentile within its industry and the 69th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.56%, ranking at the 70th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 80.5 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 4.56% total shareholder yield, 3.92% is paid out as dividends and roughly 0.64% is implied to come from buybacks — both channels are meaningfully in play. Shandong Buchang Pharmaceuticals operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.